Business
Incannex Company Presentation – Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A
MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce
About this update from Incannex Healthcare Inc.
[{"type":"text","content":"MELBOURNE, Australia, May 03, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) is pleased to announce a company presentation containing data and analysis of the results from the Phase 1 clinical trial undertaken to assess safety and pharmacokinetics of IHL-675A as an anti-inflammatory drug candidate. A Media Snippet accompanying this announcement is available by clicking on the image or link below: Incannex Contact Information: Incannex Healthcare LimitedMr Joel LathamManaging Director and Chief Executive Officer+61 409 840 [email protected] Investor Relations Contact – United StatesAlyssa FactorEdison Group+1 (860) 573 [email protected] \nSource: Incannex Healthcare","length":3033,"tagName":"div"}]